Alembic Pharmaceuticals LimitedNSE: APLLTD

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%.

· Issued by Alembic Pharmaceuticals Limited via NSE India

Filed with NSE · ISIN INE901L01018 · · 2 pages · English

Summary by 6ix AI

Alembic Pharmaceuticals Limited has received final approval from the US Food & Drug Administration for its Ciprofloxacin and Dexamethasone Otic Suspension. This approval pertains to an Abbreviated New Drug Application for a product indicated for treating specific ear infections in patients.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/alembic-pharmaceuticals-limited-receives-usfda-final-approval-for-ciprofloxacin-and-dexamethasone-otic-suspension-usp-03percent-01percent

Alembic Pharmaceuticals Limited on 6ix

Earlier from Alembic Pharmaceuticals

All Alembic Pharmaceuticals news releases